Firebrick Pharma Limited (ASX: FRE)
Health Care · Pharmaceuticals · AU
AU$0.03
+3.85% today · -63.5% 1Y
Firebrick Pharma Limited (ASX: FRE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.48M and employs 6 people.
Over the last twelve months the share price has lost 63.5%, trading between 0.02 and 0.08.
Tweenvest scores Firebrick Pharma Limited across four factors: quality 28/100, value 44/100. Its strongest factor is value.
FRE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.48M
- Revenue (TTM)
- $273.94K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.82
- 52-week high
- AU$0.08
- 52-week low
- AU$0.02
- Avg volume (3M)
- —
- Shares outstanding
- 285.20M
- Employees
- 6
- Next earnings
- —
About Firebrick Pharma Limited
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.
- Founded
- 2012
- Listed since
- Jan 27, 2022
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.22 | -0.96% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.